| Patent Designation |
Patent Number |
Definition |
Countries of Use |
| Compositions for and methods of treating muscle degeneration
and weakness |
U.S. 5,130,141 (issued)
 |
Broad pioneering patent in the field of myogenic cells
and their use for repair of damaged muscle |
United States |
| Cardiomyocytes for heart muscles damaged in heart
attacks |
U.S. Appl. No. 09/867,519 (pending)
Singapore: Appl. No. 9801012-7 (pending)
Aus.: (Appl. No. pending)
|
Method for producing cardiomyocytes capable of proliferation,
comprising providing cardiomyocyte cells; providing myoblast cells; and
mixing the two types of cells under conditions that allow cell fusion of
cardiomyocyte cells with myoblast cells to form heterokaryotic cardiomyocytes |
United States
Singapore |
| Myoblast therapy for mammalian diseases (1) |
Aus.: 58311/99 (issued)
China: Appl. No. 951925288 (PCT/US 95/16093)(issued)
Aus.: Appl. No. 45976/96 (issued)
Aus.: Appl. No. 2002300997 (pending)
Can.: Appl. No. 2183167 (pending)
Eur.: Appl. No. 95944088.4 (pending)
|
Compositions and methods for repairing degenerating
cells and replenishing lost cells in patients with hereditary degenerative
diseases, in particular hereditary neuromuscular disorders |
Australia, China, Canada, Europe (EPO) |
| Myoblast therapy for mammalian diseases
(2) |
U.S. Appl. No. 09/005,034 (issued)
Singapore Appl. No. 9611231.3 (issued)
PCT Appl. No. 9801012-7 (pending)
|
Myogenic cells that are normal, or genetically or phenotypically
altered are cultured and transplanted into malfunctioning and/or degenerative
tissues or organs to alleviate conditions that are hereditary, degenerative,
debilitating, undesirable, and/or fatal |
United States
Singapore
(a PCT patent)
|
| Myoblast transfer therapy for relieving pain and
for treating behavioral and perceptive abnormalities |
Eur.: EPO 0898967 (issued)
France: (issued)
Germany: (issued)
UK: (issued)
Italy: (issued)
Switz. & Liechtenstein: (issued)
Can.: Appl. No. 2,225,185 (pending)
HK.: Appl. No. 99102199.7 (pending)
Jap.: Appl. No. 10-227422 (pending)
Mex.: Appl. No. 982560 (pending)
U.S.: Appl. No. 09/132,321 (pending)
U.S.: Appl. No. 09/986,344 (pending)
|
A method of continuously supplying in vivo a peptide
such as an opioid peptide, substance P receptor, or substance P analog |
Europe (EPO), Canada, Hong Kong, Japan, Mexico, United
States |
| Automated cell processor |
U.S.: Patent No. 6,261,832 (issued)
Singapore Patent No. 74036 (issued)
|
An automated instrument for producing > a billion
mammalian cells per run using stacked trays and tray tilting to move fluid
into and out of the trays. |
United States, Singapore (a PCT patent) |
| Myoblast therapy for cosmetic treatment |
Singapore: Appl. No. 9801014-3 (issued)
Australia: Appl. No. 748997 (issued)
U.S.: Appl. No. 09/005,034 (issued)
|
Myoblast cells can be grown up in huge quantities and
added back, to fuse with other muscle cells and adipocytes (fat cells) to
sculpt the body |
Singapore, Australia, United States |
| Serum containing compositions and methods for cell
culture and therapy |
U.S. Provisional Patent Appl. No. 60/306,426 (pending) |
Detailed methods and strategies for successful culture
and manipulation of mammalian cells, and particularly myogenic cells in
non-defined media. Growth media and procedures presented favor myogenic
cell growth at the expense of fibroblast growth and are particularly useful
for new therapies that combat heart disease and other muscle disorders |
United States |
| Myogenic cell transfer catheter and method |
W.O. 02/28470 A1
U.S. 60/231,880 (determined issuable)
PCT/US01/28712 (pending)
Singapore Appl. No. 200301162-4 (pending)
Aus: Appl. No. 2002211230 (pending)
Can: Appl. No. 79029-39 (pending)
|
Cardiovascular catheters and methods of their use for
automatically injecting large quantities of myogenic cells for repairing
and augmenting muscle and other tissues. The catheters are "smart" devices
with built in injection timing that allows easy and more accurate injection
of cells from inside a beating heart for its repair |
United States PCT |
| Heart regeneration |
U.S. Provisional Patent Application.
Foreign License Granted. |
Composition and methods for heart regeneration using
angiomyogenesis |
United States PCT |
| Biologic skin repair and enhancement |
U.S. Provisional Patent Appl. No. 60/405,301 |
Composition and methods for beautifying and strengthening
skin |
United States |
| Cellular Transplantation for heart regeneration |
PCT/US03/95905 (pending)
U.S. Provisional Patent Appl. No. 60/368,563 (pending)
|
Angiomyogenesis of damaged hearts |
PCT
United States
|
| Mechanisms of myoblast transfer in treating heart
failure |
PCT (Appl. No. pending)
U.S. Provisional Patent Appl. No. 60/402,050 (pending)
|
Transduced myoblasts to treat hear muscle degeneration, baldness
and male sexual impotency |
PCT
United States
|
| Myoblast treatment of diseased or weakened organs |
U.S. (Appl. No. pending)
PCT (Appl. No. pending)
|
Cell therapy to treat and/or augment body structures |
United States |
Licensing
Research Licenses
- Cell Therapy Research Foundation, Memphis, TN, USA, 1992-present
- Samsung Cheil Hospital, Seoul, Korea, 1998-2001
- Yonsei University Rehab Institute of Muscular Diseases, Seoul, Korea,
1998-present
- Genesys Research Foundation, Sao Paolo, Brazil, 1998-present
- Duke University, Durham, NC, USA, 2000-present
- Biosense Webster, Newark, NJ, USA, 2000-2001
- Arizona Heart Institute and Arizona Heart Hospital, Phoenix, AZ, USA,
April 2001-present
- National University of Singapore, Singapore, Singapore, 2001
Commercial Licenses
- Bioheart, Inc., Weston, FL, USA, May 2000
Conditional Exclusive License (Non-exclusive license with a first right
of refusal) on Heart Muscle Regeneration and Angiogenesis
- Cell Transplants Singapore Pte Ltd, Singapore, Singapore
Perpetual on all IP issued in Singapore since 1999 to September 2003
- Cell Transplants International, LLC, Memphis, TN USA
EXCLUSIVE IP ASSIGNEE, LICENSING UNIT ON ALL IP
|